Cargando…

Transcranial direct current stimulation for refractory auditory hallucinations in schizophrenia: Acute and 16-week outcomes

BACKGROUND: Transcranial direct current stimulation (tDCS) has demonstrated efficacy against antipsychotic-refractory auditory verbal hallucinations (AVH) in schizophrenia. The duration of persistence of benefit is not well characterized. MATERIALS AND METHODS: Thirty-one adults with schizophrenia a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Pattath Narayanan Suresh, Krishnan, Arun Gopala, Suresh, Rohith, Andrade, Chittaranjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909021/
https://www.ncbi.nlm.nih.gov/pubmed/33678840
http://dx.doi.org/10.4103/psychiatry.IndianJPsychiatry_182_19
Descripción
Sumario:BACKGROUND: Transcranial direct current stimulation (tDCS) has demonstrated efficacy against antipsychotic-refractory auditory verbal hallucinations (AVH) in schizophrenia. The duration of persistence of benefit is not well characterized. MATERIALS AND METHODS: Thirty-one adults with schizophrenia and medication-refractory AVH were treated with 2–3 mA tDCS in 30 min sessions, twice a day, 6 days a week, for 2–4 weeks. The anode was sited over F3 and the cathode midway between T3 and P3 in the 10–20 EEG system. Patients were assessed until a 4-month study endpoint using two auditory hallucination rating scales and the Positive and Negative Syndrome Scale (PANSS-N). RESULTS: Auditory hallucinations were moderately reduced by tDCS with 25%–29% improvement evident by the end of the 2(nd) week and another 10% improvement between week 2 and 4 months. There was no loss of benefit at the end of the 4-month study. There was also a small (11%) but statistically significant improvement in PANSS-N scores. CONCLUSIONS: Although this study is limited by the nonblind, uncontrolled design, the results suggest that tDCS, as delivered, holds promise for treating refractory AVH in schizophrenia; the benefits persist beyond the short term.